Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
“I think one of the greatest attractions of bioresorbable vascular scaffolds is the idea that normal vasofunction will eventually be restored. There is some evidence from imaging data to show that the plaque is modified alongside the stent dissolving. There is also positive remodelling taking place, and this vascular response is one of the most exciting aspects of the technology.”
“There is no uniformity in these devices and no class effect. Every device needs to be assessed carefully and individually. The inflammatory response associated with these devices depends on the pace of degradation, so we need to assess how they degrade over time, and this has important implications for patient safety.”
“The long-term safety of bioresorbable vascular scaffolds will depend on various things: if we can see that arterial healing occurs over time; if full degradation occurs in the absence of excess inflammation and if we do not see too much positive remodelling, then these devices can be very beneficial to patient care,” Joner added.
“I think the technology is very interesting, but the bar that has been set by drug-eluting stents is very high and bioresorbable vascular scaffolds will need to match this, especially with regard to strut thickness and deliverability,” said Prof Chaim Lotan, Head of the Cardiovascular Insitute, Hadassah University Hospital, Jerusalem, Israel.
"We need follow-up data of more than five years’ duration, possibly up to 10 years, because our previous experience with bare metal stents and drug-eluting stents has shown that we still see changes up to seven years. So we await long-term data for bioresorbable vascular scaffolds with regard to device behaviour and degradation patterns. We have seen cases where the stent has not yet degraded after three years and this could pose a problem for patients. Will the degradation occur as planned? Will the struts be apposed? Will we see late events such as thrombosis? All these are unanswered questions,” he said.
“In general, the data emerging are in line with the theory behind these devices: that vascular restoration therapy is going to heal vessels better than metallic stents. The long-term data has been demonstrated in non-complex patients, and we see that these patients do very well. We still need more data in more complex patients; there are now some non-randomised data available that are out to six-months, but we have to wait for the evidence in more complex patients before we can advocate the use of these devices in such patients,” he said.
© 2017 European Society of Cardiology. All rights reserved